Multisystemic inflammatory syndrome in children and the BNT162b2 vaccine: a nationwide cohort study.
COVID-19
Pediatric inflammatory multisystem syndrome
Vaccine
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
received:
09
01
2024
accepted:
24
04
2024
revised:
12
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
9
5
2024
Statut:
aheadofprint
Résumé
Multisystemic inflammatory syndrome in children (MIS-C) is a rare, severe, post-infectious hyperinflammatory condition that occurs after COVID-19 infection. In this study, we aimed to demonstrate the risk reduction of MIS-C and severe MIS-C after Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccination. This nationwide cohort study included 526,685 PCR-confirmed COVID-19 cases (age < 19 years), of whom 14,118 were fully vaccinated prior to COVID-19 infection. MIS-C cases were collected from all hospitals in Israel from April 2020 through November 2021. The MIS-C rates were calculated among two COVID-19 populations: positive PCR confirmed cases and estimated COVID-19 cases (PCR confirmed and presumed). Vaccination status was determined from Ministry of Health (MoH) records. The MIS-C risk difference (RD) and 95% confidence intervals (95%CI) between vaccinated and unvaccinated patients are presented. Overall, 233 MIS-C cases under the age of 19 years were diagnosed and hospitalized in Israel during the study period. Among the estimated COVID-19 cases, MIS-C RD realistically ranged between 2.1 [95%CI 0.7-3.4] and 1.0 [95%CI 0.4-1.7] per 10,000 COVID-19 cases. For severe MIS-C, RD realistically ranged between 1.6 [95%CI 1.3-1.9] and 0.8 [95%CI 0.7-1.0], per 10,000 COVID-19 cases. Sensitivity analysis was performed on a wide range of presumed COVID-19 rates, demonstrating significant RD for each of these rates. This research demonstrates that vaccinating children and adolescents against COVID-19 has reduced the risk of MIS-C during the study period. • Most of the published literature regarding vaccine effectiveness is based on case-control studies, which are limited due to small sample sizes and the inability to fully estimate the risk of MIS-C among vaccinated and unvaccinated children and adolescents. • The known underestimation of COVID-19 diagnosis among children and adolescents is challenging, as they often have few to no symptoms. • Significant risk difference was found in favor of the vaccinated group, even after including extreme assumptions regarding the underdiagnosed COVID-19 rate. • During this nationwide study period, it was found that vaccinating children and adolescents reduced the risk of MIS-C and its complications.
Identifiants
pubmed: 38724677
doi: 10.1007/s00431-024-05586-4
pii: 10.1007/s00431-024-05586-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Feldstein LR, Tenforde MW, Friedman KG et al (2021) Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA 325:1074–1087. https://doi.org/10.1001/jama.2021.2091
doi: 10.1001/jama.2021.2091
pubmed: 33625505
Feldstein LR, Rose EB, Horwitz SM et al (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 383:334–346. https://doi.org/10.1056/NEJMoa2021680
doi: 10.1056/NEJMoa2021680
pubmed: 32598831
Riphagen S, Gomez X, Gonzalez-Martinez C et al (2020) Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395:1607–1608. https://doi.org/10.1016/S0140-6736(20)31094-1
doi: 10.1016/S0140-6736(20)31094-1
pubmed: 32386565
pmcid: 7204765
HAN Archive - 00432 | Health Alert Network (HAN). https://emergency.cdc.gov/han/2020/han00432.asp . Accessed 26 Aug 2022
Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS -CoV-2 infection in children - France | ReliefWeb. https://reliefweb.int/report/france/rapid-risk-assessment-paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2?gclid=CjwKCAjw-IWkBhBTEiwA2exyO_JVOWgIOXeu5v5GqZ8jzCO5f-R327wqYV0A-1DW4esyFe1AZlWVnRoCRSMQAvD_BwE . Accessed 8 Jun 2023
Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C) | CDC. https://www.cdc.gov/mis/mis-c/hcp/index.html . Accessed 26 Aug 2022
Nygaard U, Holm M, Hartling UB et al (2022) Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study. Lancet Child Adolesc Health 6:459–465. https://doi.org/10.1016/S2352-4642(22)00100-6
doi: 10.1016/S2352-4642(22)00100-6
pubmed: 35526537
pmcid: 9072929
Yilmaz D, Ekemen Keles Y, Emiroglu M et al (2023) Evaluation of 601 children with multisystem inflammatory syndrome (Turk MISC study). Eur J Pediatr 182:5531–5542. https://doi.org/10.1007/s00431-023-05207-6
doi: 10.1007/s00431-023-05207-6
pubmed: 37782350
Lampidi S, Maritsi D, Charakida M et al (2024) Multisystem inflammatory syndrome in children (MIS-C): a nationwide collaborative study in the Greek population. Eur J Pediatr. https://doi.org/10.1007/s00431-023-05383-5
doi: 10.1007/s00431-023-05383-5
pubmed: 38214810
pmcid: 11001744
Payne AB, Gilani Z, Godfred-Cato S et al (2021) Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw Open 4:e2116420. https://doi.org/10.1001/jamanetworkopen.2021.16420
doi: 10.1001/jamanetworkopen.2021.16420
pubmed: 34110391
pmcid: 8193431
Karagiannidis C, Sander L-E, Mall MA, Busse R (2022) Incidence and outcomes of SARS-CoV-2-associated PIMS in Germany: a nationwide analysis. Infection. https://doi.org/10.1007/s15010-022-01877-w
doi: 10.1007/s15010-022-01877-w
pubmed: 35773555
pmcid: 9246358
Whittaker R, Greve-Isdahl M, Bøås H et al (2022) COVID-19 hospitalization among children <18 years by variant wave in Norway. Pediatrics. https://doi.org/10.1542/peds.2022-057564
doi: 10.1542/peds.2022-057564
pubmed: 35916036
Cohen JM, Carter MJ, Ronny Cheung C et al (2022) Lower risk of multisystem inflammatory syndrome in children (MIS-C) with the Delta and Omicron variants of SARS-CoV-2. Clin Infect Dis. https://doi.org/10.1093/cid/ciac553
doi: 10.1093/cid/ciac553
pubmed: 35568473
pmcid: 10319953
FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine | FDA. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19 . Accessed 8 Jun 2023
Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use . Accessed 16 Mar 2024
FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age | FDA. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age . Accessed 26 Aug 2022
Lan Z, Yan J, Yang Y et al (2023) Effectiveness of COVID-19 vaccines among children and adolescents against SARS-CoV-2 variants: a meta-analysis. Eur J Pediatr 182:5235–5244. https://doi.org/10.1007/s00431-023-05216-5
doi: 10.1007/s00431-023-05216-5
pubmed: 37768334
Zambrano LD, Newhams MM, Olson SM et al (2022) Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep 71:52–58. https://doi.org/10.15585/mmwr.mm7102e1
doi: 10.15585/mmwr.mm7102e1
pubmed: 35025852
pmcid: 8757620
Yu W, Guo Y, Zhang S et al (2022) Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: a systematic review and analysis. J Med Virol 94:5790–5801. https://doi.org/10.1002/jmv.28066
doi: 10.1002/jmv.28066
pubmed: 35961786
Viner RM, Mytton OT, Bonell C et al (2021) Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr 175:143–156. https://doi.org/10.1001/jamapediatrics.2020.4573
doi: 10.1001/jamapediatrics.2020.4573
pubmed: 32975552
Tsankov BK, Allaire JM, Irvine MA et al (2021) Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 103:246–256. https://doi.org/10.1016/j.ijid.2020.11.163
doi: 10.1016/j.ijid.2020.11.163
pubmed: 33227520
Preston LE, Chevinsky JR, Kompaniyets L et al (2021) Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw Open 4:e215298. https://doi.org/10.1001/jamanetworkopen.2021.5298
doi: 10.1001/jamanetworkopen.2021.5298
pubmed: 33835179
pmcid: 8035649
Haas EJ, McLaughlin JM, Khan F et al (2022) Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis 22:357–366. https://doi.org/10.1016/S1473-3099(21)00566-1
doi: 10.1016/S1473-3099(21)00566-1
pubmed: 34562375
Population - statistical abstract of Israel 2022 - No.73. https://www.cbs.gov.il/en/publications/Pages/2022/Population-Statistical-Abstract-of-Israel-2022-No.73.aspx . Accessed 8 Jun 2023
Zambrano LD, Newhams MM, Olson SM et al (2023) BNT162b2 mRNA vaccination against coronavirus disease 2019 is associated with a decreased likelihood of multisystem inflammatory syndrome in children aged 5–18 years-United States, July 2021 - April 2022. Clin Infect Dis 76:e90–e100. https://doi.org/10.1093/cid/ciac637
doi: 10.1093/cid/ciac637
pubmed: 35924406
Reese H, Iuliano AD, Patel NN et al (2021) Estimated incidence of coronavirus disease 2019 (COVID-19) illness and hospitalization-United States, February-September 2020. Clin Infect Dis 72:e1010–e1017. https://doi.org/10.1093/cid/ciaa1780
doi: 10.1093/cid/ciaa1780
pubmed: 33237993
Buonsenso D, Perramon A, Català M et al (2022) Multisystem inflammatory syndrome in children in Western countries? Decreasing incidence as the pandemic progresses?: an observational multicenter international cross-sectional study. Pediatr Infect Dis J 41:989–993. https://doi.org/10.1097/INF.0000000000003713
doi: 10.1097/INF.0000000000003713
pubmed: 36102705
pmcid: 9645445
Munro APS, Jones CE, Faust SN (2024) Vaccination against COVID-19 - risks and benefits in children. Eur J Pediatr. https://doi.org/10.1007/s00431-023-05380-8
doi: 10.1007/s00431-023-05380-8
pubmed: 38169007
pmcid: 10950962
Laird-Gion J, Dionne A, Gauvreau K et al (2023) MIS-C across three SARS-CoV-2 variants: changes in COVID-19 testing and clinical characteristics in a cohort of U.S. children. Eur J Pediatr 182:2865–2872. https://doi.org/10.1007/s00431-023-04968-4
doi: 10.1007/s00431-023-04968-4
pubmed: 37055630
pmcid: 10101535